Abstract
To achieve bacteriologic and clinical success, sufficient concentrations of antimicrobial at the site of infection must be maintained for an adequate period of time. These dynamics are determined by combining drug pharmacokinetic and pharmacodynamic (PK/PD) data with minimum inhibitory concentrations. Bacteriologically confirmed failures have been reported in otitis media and, with a lesser degree of evidence, in pneumococcal pneumonia with a variety of agents that include β-lactams, macrolides and fluoroquinolones. These failures have been shown to be due to infection by resistant pathogens or suboptimal therapy. However, no clinical failure has been reported during therapy for bacteremic pneumococcal pneumonia with adequate doses of β-lactams. The failures reported with macrolides or fluoroquinolones have been due to either preexisting resistance to these agents that cannot be overcome by increasing the dose of the antimicrobial or, more rarely, the emergence of resistance during therapy. In this review, we offer an overview of the most important attributes of the main antimicrobials that are currently used in the treatment of community-acquired respiratory tract infections from a PK/PD perspective.
References
1.
Jacobs MR, Felmingham D, Appelbaum PC, Gruneberg RN: The Alexander Project Group. The Alexander Project 1998–2000: Susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003;52:229–246.
2.
Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, Plouffe JF, Rakowsky A, Schuchat A, Whitney CG: Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000;160:1399–1408.
3.
Linares J, Pallares R, Alonso T, Perez JL, Ayats J, Gudiol F, Viladrich PF, Martin R: Trends in antimicrobial resistance of clinical isolates of Streptococcus pneumoniae in Bellvitge Hospital, Barcelona, Spain (1979–1990). Clin Infect Dis 1992;15:99–105.
4.
Ball P, Baquero F, Cars O, File T, Garau J, Klugman K, Low DE, Rubinstein E, Wise R: Consensus Group on Resistance and Prescribing in Respiratory Tract Infection. Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. J Antimicrob Chemother 2002;49:31–40.
5.
Song JH: Introduction: The goals of antimicrobial therapy. Int J Infect Dis 2003;7(suppl 1):S1–S4.
6.
Andes D, Craig WA: Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002;19:261–268.
7.
Cazzola M, Matera MG, Pezzuto G: Inflammation – A new therapeutic target in pneumonia. Respiration 2005;72:117–126.
8.
Andes D, Anon J, Jacobs M, Craig WA: Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin Lab Med 2004;24:477–502.
9.
Craig WA: Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. J Antimicrob Chemother 1993;31 (suppl D):149–158.
10.
Cars O, Odenholt-Tornqvist I: The post-antibiotic sub-MIC effect in vitro and in vivo. J Antimicrob Chemother 1993;31(suppl D): 159–166.
11.
McDonald PJ, Wetherall BL, Pruul H: Postantibiotic leukocyte enhancement: Increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes. Rev Infect Dis 1981;3:38–44.
12.
Zhao X, Drlica K: Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis 2001;33:S147–156.
13.
Zhao X, Drlica K: Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J Infect Dis 2002;185:561–565.
14.
Craig WA: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1–12.
15.
Craig WA: Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. Infect Dis Clin North Am 2003;17:479–501.
16.
Jacobs MR: Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters. Clin Microbiol Infect 2001;7:589–596.
17.
Mouton JW, Touzw DJ, Horrevorts AM, Vinks AA: Comparative pharmacokinetics of the carbapenems: clinical implications. Clin Pharmacokinet 2000;39:185–201.
18.
Craig WA, Suh B: Protein binding and the antimicrobial effects: methods for the determination of protein binding; in Lorian V (ed): Antibiotics in Laboratory Medicine, ed 3. Baltimore, Williams & Wilkins, 1991, pp 367–402.
19.
Craig W, Kiem S, Andes D: Free drug 24 h AUC/MIC is the PK (PD target that correlates with in vivo efficacy of macrolides, azalides, ketolides and clindamycin (abstract A-1263). Program 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, 2002.
20.
Schentag JJ: Antimicrobial action and pharmacokinetics/pharmacodynamics: The use of AUIC to improve efficacy and avoid resistance. J Chemother 1999;11:426–439.
21.
Leggett JE, Ebert S, Fantin B, Craig WA: Comparative dose-effect relations at several dosing intervals for beta-lactam, aminoglycoside and quinolone antibiotics against gram-negative bacilli in murine thigh-infection and pneumonitis models. Scand J Infect Dis Suppl 1990;74:179–184.
22.
Schentag JJ: Clinical pharmacology of the fluoroquinolones: studies in human dynamic/kinetic models. Clin Infect Dis 2000;3:S40–S44.
23.
Craig WA, Redington J, Ebert SC: Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991;27(suppl C):29–40.
24.
Fass RJ: Aetiology and treatment of community-acquired pneumonia in adults: an historical perspective. J Antimicrob Chemother 1993;32(suppl A):17–27.
25.
Garau J: Role of beta-lactam agents in the treatment of community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005;24:83–99.
26.
Forward KR: The epidemiology of penicillin resistance in Streptococcus pneumoniae. Semin Respir Infect 1999;14:243–254.
27.
Song JH, Lee NY, Ichiyama S, Yoshida R, Hirakata Y, Fu W, Chongthaleong A, Aswapokee N, Chiu CH, Lalitha MK, Thomas K, Perera J, Yee TT, Jamal F, Warsa UC, Vinh BX, Jacobs MR, Appelbaum PC, Pai CH: Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) Study. Clin Infect Dis 1999;28:1206–1211.
28.
Buckingham SC, Brown SP, Joaquin VH: Breakthrough bacteremia and meningitis during treatment with cephalosporins parenterally for pneumococcal pneumonia. J Pediatr 1998;132:174–176.
29.
Sacho H, Klugman KP, Koornhof HJ, Ruff P: Community-acquired pneumonia in an adult due to a multiply-resistant pneumococcus. J Infect 1987;14:188–189.
30.
Feldman C, Kallenbach JM, Miller SD, Thorburn JR, Koornhof HJ: Community-acquired pneumonia due to penicillin-resistant pneumococci. N Engl J Med 1985;313:615–617.
31.
Dagan R, Abramson D, Leibovitz E, et al: Impaired bacteriologic response to oral cephalosporins in acute otitis media caused by pneumococci with intermediate resistance to penicillin. Pediatr Infect Dis 1996;15:980–985.
32.
Klein JO: Microbiologic efficacy of antibacterial drugs for acute otitis media. Pediatr Infect Dis J 1993;12:973–975.
33.
Ewing S, Ruiz M, Torres A, Marco F, Martínez JA, Sanchez M, et al: Pneumonia acquired in the community through drug-resistant Streptococcus pneumoniae. Am J Respir Crit Care Med 1999;159:1835–1842.
34.
Bedos J Chardon H, Jeh F, et al: Impact of penicillin resistance in community-acquired pneumococcal pneumonia in adults hospitalised patients: Findings of a French national prospec tive survey (abstract L-851). 41st Interscience Conference on Antimicroglial Agents and Chemotherapy, Chicago, December, 2001.
35.
Moroney JF, Fiore AE, Harrison LH, Patterson JE, Farley MM, Jorgensen JH, Phelan M, Facklam RR, Cetron MS, Breiman RF, Kolczak M, Schuchat A: Clinical outcomes of bacteremic pneumococcal pneumonia in the era of antibiotic resistance. Clin Infect Dis 2001;33:797–805.
36.
Quach C, Weiss, Moorer D, Rubin E, Restieri C: Clinical presentation, outcome, cost and risk factors associated with invasive Streptococcus pneumoniae infections in a paediatric population: a case control study (abstract 1862). 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September, 2000.
37.
Yu VL, Chiou CCC, Feldman C, Ortqvist A, Rello J, Morris AJ, et al: An international prospective study of pneumococcal bacteraemia: correlation with in vitro resistance, antibiotics administered and clinical outcome. Clin Infect Dis 2003;37:230–237.
38.
Turett GS, Blum S, Fazal BA, Justman JE, Telzak EE: Penicillin resistance and other predictors of mortality in pneumococcal bacteremia in a population with high human immunodeficiency virus seroprevalence. Clin Infect Dis 1999 ;29:321–327.
39.
Feikin DR, Schuchat A, Kolczak M, Barrett NL, Harrison LH, Lefkowitz L, McGeer A, Farley MM, Vugia DJ, Lexau C, Stefonek KR, Patterson JE, Jorgensen JH: Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995–1997. Am J Public Health 2000;90:223–229.
40.
Metlay JP, Hofmann J, Cetron MS, Fine MJ, Farley MM, Whitney C, Breiman RF: Impact of penicillin susceptibility on medical outcomes for adult patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2000;30:520–528.
41.
Goldstein FW, Garau J: 30 years of penicillin-resistant S. pneumoniae: Myth or reality. Lancet 1997;350:233–234.
42.
Azoulay-Dupuis E, Rieux V, Muffat-Joly M, et al: Relationship between capsular type, penicillin susceptibility and virulence of human Streptococcus pneumoniae isolates in mice. Antimicrob Agents Chemother 2000;44:1575–1577.
43.
Woodnutt G, Berry V: Efficacy of high dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1999;43:35–40.
44.
Van Kerkhoven D, Peetermans WE, Verbist L, Verhaegen J: Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral beta-lactams. J Antimicrob Chemother 2003;51:691–696.
45.
Urban A, Andes D, Craig WA: In vivo activity of cefpodoxime against penicillin-resistant pneumococci (abstract 2229); in Abstracts 19th International Congress of Chemotherapy, Montreal. Can J Infect Dis 1995:6:381C.
46.
Carratala J, Marron A, Fernandez-Sevilla A, Linares J, Gudiol F: Treatment of penicillin-resistant pneumococcal bacteremia in neutropenic patients with cancer. Clin Infect Dis 1997;24:148–152.
47.
Weisblum B: Erythromycin resistance by ribosome modification. Antimicrob Agents Chemother 1995;39:577–585.
48.
Johnston N, de Azavedo J, KellnerJ, Low K: Prevalence and characterization of the mechanisms of macrolide, lincosamide and streptogramin resistance in isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 1998;42:2425–2426.
49.
Tait-Kamradt A, Davies T, Appelbaum PC, Depardieu F, Courvalin P, Petitpas J, Wondrack L, Walker A, Jacobs MR, Sutcliffe J: Two new mechanisms of macrolide resistance in clinical strains of Streptococcus pneumoniae from Eastern Europe and North America. Antimicrob Agents Chemother 2000;44:3395–3401.
50.
Tait-Kamradt A, Davies T, Cronan M, Jacobs MR, Appelbaum PC, Sutcliffe J: Mutations in 23S rRNA and ribosomal protein L4 account for resistance in pneumococcal strains selected in vitro by macrolide passage. Antimicrob Agents Chemother 2000;44:2118–2125.
51.
Farrell DJ, Morrissey I and the PROTEKT Study group: Distribution of macrolide resistance mechanisms in Streptococcus pneumoniae: 3-year update from the Protekt Study (abstract P1148). Program and Abstracts of the 14th European Congress of Clinical Microbiology and Infectious Diseases. Prague, 2004.
52.
Brown SD, Gogg DA: Trends in antimicrobial resistance among Streptococcus pneumoniae from respiratory tract infections: PROTEKT US Y1 and Y2. Program and Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy (abstract C2–925). Chicago, 2003.
53.
Lonks JR, Garau J, Gomez L, Xercavins M, Ochoa de Echaguen A, Gareen IF, et al: Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002;35:556–564.
54.
Jacobs MR: Building in efficacy: developing solutions to combat drug-resistant S. pneumoniae. Clin Microbiol Infect 2004;10(suppl 2): 18–27.
55.
Craig WA, Andes D: Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J 1996;15:255–259.
56.
Craig WA: Does the dose matter? Clin Infect Dis 2001:33:S233–S237.
57.
Jacobs MR, Bajaksouzian S, Zilles A, Lin G, Pankuch GA, Appelbaum PC: Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 US Surveillance study. Antimicrob Agents Chemother 1999;43:1901–1908.
58.
Dagan R, Leibovitz E, Fliss DM, Leiberman A, Jacobs MR, Craig W, Yagupsky P: Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000;44:43–50.
59.
Dagan R, Leibovitz E, Fliss DM, Leiberman A, Jacobs MR, Craig W, Yagupsky P: Bacteriologic efficacies of oral azithromycin and oral cefaclor in treatment of acute otitis media in infants and young children. Antimicrob Agents Chemother 2000;44:43–50.
60.
Drusano G: Pharmacodynamic and pharmacokinetic considerations in antimicrobial selection: focus on telithromycin. Clin Microbiol Infect 2001;7:S24–S29.
61.
Kim MK, Zhou W, Tessier PR, Xuan D, Ye M, Nightingale CH, Nicolau DP: Bactericidal effect and pharmacodynamics of cethromycin (ABT-773) in a murine pneumococcal pneumonia model. Antimicrob Agents Chemother 2002;46:3185–3192.
62.
Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG: A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000;283:749–755.
63.
Leroy O, Saux P, Bedos JP, Caulin E: Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005;128:172–183.
64.
Pan XS, Ambler J, Mehtar S, Fisher LM: Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae. Antimicrob Agents Chemother 1996;40:2321–2326.
65.
Ambrose PG, Grasela DM, Grasela TH, Passarell J, Mayer H, Pierce P: Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2001;45:2793–2797.
66.
Lister PD: Pharmacodynamics of gatifloxacin against Streptococcus pneumoniae in an in vitro pharmacokinetic model: impact of area under the curve/MIC ratios on eradication.Antimicrob Agents Chemother 2002;46:69–74.
67.
Wright DH, Brown GH, Peterson ML, Rotschafer JC: Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother 2000;46:669–683.
68.
Cooper B, Lawlor M: Pneumococcal bateremia during ciprofloxacin therapy for pneumococcal pneumonia. Am J Med 1989;87:475.
69.
Rigther J: Pneumococcal meningitis during intravenous ciprofloxacin therapy. Am J Med 1990;88:548.
70.
Lee BL, Padula A, Kimbrough RC, et al: Infectious complications with respiratory pathogens despite ciprofloxacin therapy. N Engl J Med 1991;325:520–521.
71.
Blondeau JM, Zhao X, Hansen G, Drlica K: Mutant prevention concentrations of fluorquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001;45:433–438.
72.
Wispelwey B: Clinical implications of pharmacokinetics and pharmacodynamics of fluoroquinolones. Clin Infect Dis 2005:41:S127–135.
73.
Allen GP, Kaatz GW, Rybak MJ: Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2003;47:2606–2614.
74.
Kishii R, Rtakei M, Fukuda H, et al: Contributions of the 8-methoxy group to the activiy of gatifloxacin against type II topoisomersaes of Streptococcus pneumoniae. Antimicrob Agents Chemother 2003;47:77–81.
75.
Schmitz F-J, Boos M, Mayer S, et al: Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae. Antimicrob Agent Chemother 2001;45:2666–2667.
76.
Perez-Trallero E, Fernandez-Mazarrasa C, Garcia-Rey C, Bouza E, Aguilar L, Garcia-de-Lomas J, Baquero F: Spanish Surveillance Group for Respiratory Pathogens. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: Results of a 1-year (1998–1999) multicenter surveillance study in Spain. Antimicrob Agents Chemother 2001;45:3334–3340.
77.
Garau J: Performance in practice: Bacteriological efficacy in patients with drug-resistant S. pneumoniae. Clin Microbiol Infect 2004;10:S28–S35.
78.
Li X, Zhao X, Drlica K: Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob Agents Chemother 2002;46:522–524.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
